Conflict of interest: Steve Cramer has served as a paid consultant to Stem Cell Therapeutics, GlaxoSmithKline, Microtransponder, and Pfizer/Cogstate.
Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial)
Version of Record online: 3 MAR 2014
© 2014 The Authors. International Journal of Stroke © 2014 World Stroke Organization
International Journal of Stroke
Volume 9, Issue 3, pages 321–327, April 2014
How to Cite
Cramer, S. C., Hill, M. D. and REGENESIS-LED Investigators (2014), Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial). International Journal of Stroke, 9: 321–327. doi: 10.1111/ijs.12260
Clinicaltrials.gov ID # NCT00938314
Funding: This study was funded by Stem Cell Therapeutics.
- Issue online: 17 MAR 2014
- Version of Record online: 3 MAR 2014
- Manuscript Accepted: 14 OCT 2013
- Manuscript Received: 22 JUN 2013
- Stem Cell Therapeutics
Table S1. Schedule of testing.
Table S2. List of serious adverse events.
Table S3. List of all adverse events.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.